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Abstract
We report a family with domestic exposure to asbestos and multiple cancers, including eight
pleural malignant mesotheliomas and several other lung/pleural tumors.  DNA sequence
analysis revealed no evidence for an inherited mutation of BAP1. Sequence  analysis of other
potentially relevant genes, including TP53, CDKN2A and BARD1, also revealed no mutations.
DNA microarray analysis of two mesotheliomas revealed multiple genomic imbalances including
consistent losses of overlappping segments in 2q, 6q, 9p, 14q, 15q and 22q, but no losses of
chromosome 3 harboring the BAP1 locus.  However, immunohistochemistry demonstrated loss
of nuclear BAP1 staining in 3 of 6 mesotheliomas tested, suggesting that somatic alterations of
BAP1 occurred in a subset of tumors from this family. Since mesothelioma could be confirmed
in only a single generation, domestic exposure to asbestos may be the predominant cause of
mesothelioma in this family. Given the existence of unspecified malignant pleural tumors and
lung cancers in a prior generation, the possibility that some other tumor susceptibility or modifier
gene(s) may contribute to the high incidence of mesothelioma in this family is discussed.
Because the incidence of mesothelioma in this family is higher than expected even in heavily
exposed asbestos workers, we conclude that both asbestos and genetic factors have played a
role in the high rate of mesothelioma and potentially other pleural/lung cancers seen in this
family.
Introduction
Malignant mesothelioma (MM) is an uncommon cancer associated with asbestos exposure.
Familial clustering in close relatives has been described in multiple reports and cannot be
explained by chance alone (1).  In addition to shared asbestos exposures, MM clustering in
some families may suggest the contribution of inherited genes (low-penetrance alleles) in the
development of this malignancy.  A genetic factor predisposing to MM was recently discovered,
namely germline mutation of the BAP1 (BRCA1-associated protein 1) gene in two families with
a high incidence of MM and only modest exposure to asbestos (2, 3).  The association of
germline BAP1 mutations with familial MM has been confirmed in a series of recent reports (4-
7).  Germline BAP1 mutations have also been repeatedly associated with other tumor types,
including uveal melanomas, cutaneous melanomas, benign melanocytic tumors, kidney
cancers, and basal cell carcinomas (3-14).  Somatic mutations and/or deletions have been
described in MMs of both individuals with germline BAP1 mutations and in sporadic cases, i.e.,
lacking a germline mutation (3, 15, 16).  Based on these findings, we decided to analyze the
BAP1 status in a family with many cases of pleural MM and asbestos exposure.
Materials and methods
Family History and Patient Samples. Over the past 18 years, since the identification of the
index patient (III-2) in 1996 and the description of four MM cases (17), we have continued to
follow this Italian family with multiple cases of MM and other malignancies (Fig. 1).  Metaphase-
based comparative genomic hybridization (CGH) analysis on tumor samples uncovered DNA
losses involving 1p, 6q, 9p, 13q, and 14q (18), each of which is a chromosomal arm that is
commonly lost in sporadic MM (19). An update of the history of this extended family was
published in 2014 (2). Between 1987 and 2012, there were six women (mean age 62 yrs) and
two men (mean age 67 yrs) who developed pleural MM in generation III. In addition to the eight
confirmed MMs, two female family members in a prior generation (II-3 and II-8) had pleural
cancers (highly suspicious of MM but unconfirmed), without radiological evidence of a primary
tumor in the lung or elsewhere. The kindred had exposure to asbestos in the domestic setting;
we demonstrated the presence of asbestos in lung tissue of two subjects, using transmission
electron microscopy (III-5: crocidolite, elevated fiber burden and asbestos bodies) and optical
microscopy (III-2: asbestos bodies). All MM patients in this family are deceased.  Formalin-
fixed, paraffin-embedded (FFPE) tissues from six MM cases were available for the mutation and
immunohistochemical studies presented here.
Sequence Analysis.  PCR products encompassing all exons and intronic splice regions of BAP1
were amplified for sequencing. Primer pairs are listed in Table 1.  Primers consisted of M13-F
and M13-R sequences incorporated at the 5’ end to facilitate sequencing. PCR products were
gel purified and sequenced using M13-For (GTAAAACGACGGCCAGT) and M13-Rev
(CAGGAAACAGCTATGAC) primers. Primers for TP53, CDKN2A and BARD1 are also  shown
in Table 1.
Immunohistochemistry.  Immunohistochemical detection of BAP1 in FFPE tumor tissues was
performed using a BAP1 antibody (C4, from Santa Cruz Biotechnology, Santa Cruz, CA), as
previously described (15).
Chromosome Microarray Analysis (CMA).  CMA was performed using Affymetrix Oncoscan
arrays.  Total genomic DNA from each test sample was digested with NspI restriction enzyme
and ligated to adapters that recognize cohesive 4-basepair (bp) overhangs.  A generic primer
that recognizes the adapter sequence was then used to amplify the adapter-ligated DNA
fragments.  Amplification products were purified using magnetic beads, fragmented, biotin-
labeled, and hybridized to arrays according to the manufacturer’s recommendations.  The
hybridized array was then washed and scanned with a GeneChip Scanner 3000 7G.  Intensities
of probe hybridization were analyzed by using Affymetrix’s GeneChip Command Console, and
copy number and genotyping analyses were performed using Affymetrix Chromosome Analysis
Suite software with default settings.
Results
To ascertain the potential involvement of a BAP1 mutation, Sanger sequencing was performed
on samples from family members III-1, III-2, III-5, and III-7.  No mutations were identified. We
also sequenced the CDKN2A gene in one specimen (III-5) to assess the possibility of a
germline point mutation.  No mutation was identified, although we did detect a common
polymorphism (designated rs11515) in the 3’UTR that does not appear to affect the gene in any
obvious way. Additionally, no mutations were identified in TP53 in four tumor tumor tissues
from this family.
CMA studies of two MMs revealed multiple genomic imbalances in each tumor.  No DNA copy
number losses or loss of heterozygosity of chromosome 3, site of the BAP1 locus (3p21), were
observed in either  tumor.  However, overlapping losses of segments in 2q, 6q, 9p, 14q, 15q
and 22q were identified (Fig. 2).  These and other  variable alterations are summarized in Table
3. Sequence analysis of the BRCA1-associated ring domain 1 gene, BARD1, located at 2q35
 within the region of overlapping deletions in 2q revealed no mutation in this gene in pleural
fluid cells from case III-05.
In three tumors (cases III-2, III-5, and III-6), BAP1 immunohistochemistry showed nuclear
staining (Fig. 3A; III-2 not shown). The other three tumors tested (III-1, III-7 and III-17) showed
loss of BAP1 nuclear staining (Fig. 3B; III-7 not shown). Cytoplasmic staining for BAP1 was
observed in four tumors, two in association with nuclear positivity (III-5, III-6; Fig. 3A) and two in
tumors lacking nuclear staining (III-1, III-7; Fig. 3B; III-7 not shown).
Discussion
Recent studies have revealed germline mutations of BAP1 in familial MM (3-7).  In the family
presented here, no evidence for an inherited BAP1 mutation was identified, although loss of
nuclear BAP1 staining was observed in 3 (III-1, III-7 and III-17) of 6 MMs tested, suggesting that
somatic genetic inactivation of BAP1 occurred in a subset of tumors.  Thus, while sequencing of
BAP1 in MMs from individuals III-1 and III-7 did not reveal any mutation, loss of nuclear BAP1
staining in these two samples may have occurred via large somatic deletions of the gene, which
would not be identified by BAP1 sequencing.  Alternatively, somatic epigenetic silencing of
BAP1 may have occurred in these cases.
The high incidence of MM in this family occurred within one generation and did not appear to be
transmitted vertically.  However, the presence of other cancers in generation II leaves open the
possibility of vertical transmission of a cancer susceptibility locus or loci.  The family is known to
have exposure to asbestos in recent generations, which presumably accounts for the MM
clustering among blood-related relatives. By interviewing individual III-17, it emerged that she
and her cousin (III-15) during their childhood frequented with assiduity the proband’s home (III-
2), whereas individuals III-14 and III-16 did not. The occurrence of two pleural cancer (highly
suspicious of MM) in subjects blood-unrelated between them (II-3, proband’s mother and II-8,
proband’s aunt) highlights the possibility of shared domestic exposure, because they frequented
the same home. Nevertheless, the aggregation of MM in generation III and the finding of lung
cancer (II-5), liver cancer (II-6) and pleural cancer (II-8) in generation II in subjects blood-related
to the proband is very striking and suggests the involvement of one or more unknown genetic
factors.
Since germline BAP1 mutations have been shown to be involved in a tumor syndrome
consisting of not just MM but also other tumor types such as cutaneous melanoma, and given
that germline mutations of CDKN2A mutations have been identified in some families with a high
incidence of cutaneous melanoma (20), sequencing of CDKN2A was performed in one case (III-
5) to determine whether a germline CDKN2A mutation might be responsible for the high
incidence of MM in this family.  The identified polymorphism in CDKN2A is designated by the
Single Nucleotide Polymorphism Database (dbSNP) as rs11515.  According to information
provided in the 1000 Genomes Project, this minor allele occurs with a frequency of 11.5% in the
general population.  Given the high frequency of this allele, it is unlikely that this variant has a
role in MM susceptibility observed in the family presented here.  Also, a literature search was
performed, using the terms ‘rs11515’ and ‘cancer’
(http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=rs11515++cancer), and nearly all the
published work indicates that this polymorphism does not increase a person’s risk for any type
of cancer. Since somatic mutations of TP53 occur in ~15% of MMs (21), and germline mutation
of TP53 predisposes to a variety of cancers in patients with Li-Fraumeni Syndrome, we also
searched for mutations in this gene in MMs from four members of the family reported here.  No
point mutations in TP53 were observed.
In summary, an inherited BAP1 mutation does not appear to be involved in the high
incidence of MM in the family reported here.  Since MM does not appear to be transmitted
vertically from one generation to the next, it appears likely that domestic asbestos exposure is
the predominant cause of MM in this extended family. However, it is still possible that another
susceptibility locus may contribute to the high incidence of MM and other pleural and lung
cancers seen in this family.  Experimental evidence with knockout mouse models demonstrate
that heterozygous germline mutations of tumor suppressor genes such as Cdkn2a and Bap1
are more prone to the development of asbestos-induced MM than genetically normal (wild-type)
littermates, but given a sufficient amount of exposure to these carcinogenic fibers, even wild-
type mice will develop MM (22, 23).  Given that our proband’s immediate family experienced
certain asbestos exposure in a domestic setting, exposure alone might have been sufficient to
cause a high incidence of MM.  Notably, however, the proportion of asbestos-exposed
individuals who develop MM, even among those who have been heavily exposed
occupationally, generally is relatively small.  While familial risk for MM has not yet been fully
determined to date, an increased risk has been reported among blood relatives in cohorts
wherein estimates of asbestos exposure levels for families of workers are known (24).  Thus, we
speculate that both asbestos and genetic factors have played a role in the high rate of MM and
pleural/lung cancers seen in the family presented here.
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Figure Legends
Figure 1. Pedigree showing multiple family members with pleural malignant mesothelioma
(MM) in first-degree (6 cases) and third-degree (2 cases) relatives of the proband (arrow) as
well as additional cancers in relatives of both paternal and maternal lines.  Other malignancies
involved the pleura (II-3 and II-8), larynx (III-3), lung (II-5, II-9, and III-12), breast (III-14), liver (II-
6), and colon (I-1).  Breast cancer also occurred in two MM patients (III-2, III-7) at early ages.
Figure 2. BAP1 immunostaining of MM cells.  A) BAP1 nuclear positive staining in cases III-5
and III-6. B) Lack of BAP1 nuclear staining in MM cells from cases III-1 and III-17.
Note cytoplasmic immunostaining in MM cells associated either with BAP1 nuclear positivity (III-
5 and III-6 in A) or negativity (III-1 in B); note BAP1 nuclear staining in normal stromal cells and
lymphocytes (III-17 in B).
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Table 1
BAP1 Exons Forward primer Reverse Primer
1 GTAAAACGACGGCCAGTGAGCCCAGAGGCGGAGCAG CAGGAAACAGCTATGACGTCAGGCAGGCGCGTC
2 GTAAAACGACGGCCAGTGACGCGCCTGCCTGAC CAGGAAACAGCTATGACCTTGACACCTGCGATGAGGAA
3 GTAAAACGACGGCCAGTCTCACTCATCAGGGGCTGTC CAGGAAACAGCTATGACCAGCACTCTGGGTGTAAGGG
4 GTAAAACGACGGCCAGTAGTGATGACGCAGTGCAAAG CAGGAAACAGCTATGACCTCCATTTCCACTTCCCAAG
5 GTAAAACGACGGCCAGTGAGGGGTGCTGTGTATGGG CAGGAAACAGCTATGACCTGTGAGCCAGGATGAAGGC
6 GTAAAACGACGGCCAGTTGTGTTCCTTCCGATTCCTGG CAGGAAACAGCTATGACAAACAGAGTCAGGGCCCAAAA
7 GTAAAACGACGGCCAGTGGTGGGAGTAGGGGGAGTATC CAGGAAACAGCTATGACGGTAGGCAGAGACACCCAAC
8 GTAAAACGACGGCCAGTCAGGGTTTCCTTCTCGCTGA CAGGAAACAGCTATGACCCCAAAGTAGGTACAGCTCCAG
9 GTAAAACGACGGCCAGTCCTGCCAGGATATCTGCCTC CAGGAAACAGCTATGACTCAGAGACAAATGCTGTGGG
10 GTAAAACGACGGCCAGTAGGTCCTCAGCCCTTAGCTATT CAGGAAACAGCTATGACTCAGACATTAGCGGGTGGCTC
11 GTAAAACGACGGCCAGTGGAGGTCCTGCCTGTGTTC CAGGAAACAGCTATGACTCAAGTAGAGAATCCTGCAAGGG
12 GTAAAACGACGGCCAGTCCGAGCAGCACTTGTTTGTA CAGGAAACAGCTATGACGGGATCCGAAGCACCTAGAAC
13a GTAAAACGACGGCCAGTCGTTCCCTTGCTTCACATCTTCT CAGGAAACAGCTATGACCCGCTGCTAGTCTTGATGGA
13b GTAAAACGACGGCCAGTTGGCTGAGAAGCTCAAAGAGTC CAGGAAACAGCTATGACCGCGTCGGGTTGGCTG
13c GTAAAACGACGGCCAGTAGTACAGACACGGCCTCTGA CAGGAAACAGCTATGACGGTTGTAGCGTATGCAGTCAAC
13d GTAAAACGACGGCCAGTCCCACATCTCCAAGGTGCTT CAGGAAACAGCTATGACCCTCCTGGGTGCACCAA
14 GTAAAACGACGGCCAGTAAAGTGTCCTGCACTCTGATGATT CAGGAAACAGCTATGACGCCTTACCCTCTGCCAGGATTA
15 GTAAAACGACGGCCAGTGCATGGACTCGCTGCTCATC CAGGAAACAGCTATGACTGGGTCCTTCTCTGGTCATCAA
16 GTAAAACGACGGCCAGTTCTGGCAAGATTGGCTCCAG CAGGAAACAGCTATGACCTCAGCAGGGCATTCCAGTTA
17 GTAAAACGACGGCCAGTCATGAGAGCCTCAGCTCCT CAGGAAACAGCTATGACGCAAGAGTGGGCTGCAGAG
CDKN2A  Exons Forward primer Reverse Primer
1beta GTAAAACGACGGCCAGTGCGCGCTCAGGGAAGG CAGGAAACAGCTATGACACAAAACAAGTGCCGAATGC
1alpha GTAAAACGACGGCCAGTGAGCGCGGCTGGGAG CAGGAAACAGCTATGACCAGAGTCGCCCGCCATC
2 GTAAAACGACGGCCAGTTTAGACACCTGGGGCTTGTG CAGGAAACAGCTATGACTGGAAGCTCTCAGGGTACAA
3 GTAAAACGACGGCCAGTTTTCAATGCCGGTAGGGACG CAGGAAACAGCTATGACAAACGATGCTGTCTTCCATGC
TP53  Exons Forward primer Reverse Primer
1 GTAAAACGACGGCCAGTGGCGGATTACTTGCCCTTACTT CAGGAAACAGCTATGACGCCCGTGACTCAGAGAGGAC
2 GTAAAACGACGGCCAGTAGGGTTGGAAGTGTCTCAT CAGGAAACAGCTATGACGGGACTGTAGATGGGTGAA
3 GTAAAACGACGGCCAGTCCTGGTCCTCTGACTGCTCTTTT CAGGAAACAGCTATGACGAAGTCTCATGGAAGCCAGCC
4a GTAAAACGACGGCCAGTAAATTAGCCAGGCATGGTG CAGGAAACAGCTATGACGTGGAATCAACCCACAGC
4b GTAAAACGACGGCCAGTTCACTTGTGCCCTGACTTTCAA CAGGAAACAGCTATGACCAGTGAGGAATCAGAGGCCTG
5 GTAAAACGACGGCCAGTGGTCCCCAGGCCTCTGATT CAGGAAACAGCTATGACGACAACCACCCTTAACCCCTC
6 GTAAAACGACGGCCAGTTTGCCACAGGTCTCCCCA CAGGAAACAGCTATGACGGGCACAGCAGGCCAG
7 GTAAAACGACGGCCAGTGATTTCCTTACTGCCTCTTGCTTCT CAGGAAACAGCTATGACAGTGAATCTGAGGCATAACTGCAC
8 GTAAAACGACGGCCAGTTGCAGTTATGCCTCAGATTCACTT CAGGAAACAGCTATGACTGAGTGTTAGACTGGAAACTTTCCA
9 GTAAAACGACGGCCAGTGGCAGTGATGCCTCAAAGA CAGGAAACAGCTATGACGCAGGCTAGGCTAAGCTATG
10 GTAAAACGACGGCCAGTCAATTGTAACTTGAACCATC CAGGAAACAGCTATGACGGATGAGAATGGAATCCTAT
11 GTAAAACGACGGCCAGTGTGTGGCCACCATCTTG CAGGAAACAGCTATGACCAAAGCAAATGGAAGTCCTG
BARD1  Exons Forward primer Reverse Primer
1  GTAAAACGACGGCCAGTGGAAGAGCTTGGCCGGTTTC  CAGGAAACAGCTATGACTACTATATCCCCCGGCAGGT
2  GTAAAACGACGGCCAGTCCAGGGAGTAACAGCCTTTCA  CAGGAAACAGCTATGACACAATAGGTTACTTTGCAGACTTTG
3  GTAAAACGACGGCCAGTCCTCTGCTCCATTTATTTCTGTTCA  CAGGAAACAGCTATGACCGTATTCCAGAACTCCAGATAGAT
4a  GTAAAACGACGGCCAGTCACACTCTAGGAGCTGAGAAAGAA  CAGGAAACAGCTATGACTCCTCTTTGGAGTCAAATTCACC
4b  GTAAAACGACGGCCAGTAGGGCTAAAAAGGCTTCTGCAA  CAGGAAACAGCTATGACTGAGGGCACCGTTTGCTTA
4c  GTAAAACGACGGCCAGTAATGGAAAACGTGGCCATCAC  CAGGAAACAGCTATGACTCTGGTTCAGAGGAAGTATCATGT
5  GTAAAACGACGGCCAGTACAGTAGCCTTAAGAGAAAACGA  CAGGAAACAGCTATGACAGAGTATATGTGGCAGAGGATGA
6  GTAAAACGACGGCCAGTAATTTACTGCCTGACGTTTACATT  CAGGAAACAGCTATGACAAGGGCATGAAGGCTGATTATGA
7  GTAAAACGACGGCCAGTTGAGTTCAGCAGCTTTTGATTCTA  CAGGAAACAGCTATGACTGTAAGCAATTGGTCAAATGGAA
8  GTAAAACGACGGCCAGTGGTTCTGGGTGTAGATTCAATGG  CAGGAAACAGCTATGACGTATACAGCCATCTCCCAATGGT
9  GTAAAACGACGGCCAGTATTGATGGCCAGGTTAGAGAACT  CAGGAAACAGCTATGACCAAAATGCAGTGACTAACCAGAGG
10  GTAAAACGACGGCCAGTCTGCCATGAAGAAGAAAAACCACT  CAGGAAACAGCTATGACACTGCTCATCGTGATCATCTTTC
11a  GTAAAACGACGGCCAGTTCTGAAATGCTTCTCCTCCAAATG  CAGGAAACAGCTATGACGGAAGCAACTCAAAGGACATCAC
11b  GTAAAACGACGGCCAGTCATACCATGCGAGACCCGAT  CAGGAAACAGCTATGACTGACTGGGCTCTCACAAACC
Table  2. Histopathological and genetic findings in six family members with MM.
Case Histology Ageat dx.
BAP1
nuclear
staining
BAP1 tumor
sequencing
status
CDKN2A
sequencing
status
Chromosome
Microarray
Losses§
Chromosome
Microarray
Gains§
III-1 Epithelial 59 negative No mutation Not done X, 2q, 6q13-qter, 8pter-q12, 9p, 9q, 14,15q11-q21.1, 22
6pter-q13, 8q12-q24,
15q21.1-qter
III-2 Sarcomatoid(desmoplastic) 66 positive No mutation Not done Not done Not done
III-5 Mixed 66 positive No mutation Polymorphism500C>G in 3'UTR
1p, 1p, 2q, 4, 6q, 9p, 10q, 11p, 14, 15q11-
q21.1, 18p, 20p, 22 15q21.1-qter
III-6 Epithelial 71 positive Not done Not done Not done Not done
III-7 Epithelial 56 negative No mutation Not done Not done Not done
III-17 Epithelial 71 negative Not done Not done Not done Not done
